

50. Wareing, M.; Shea, A.; Inglis, C.; Dias, P.; Sarawar, S. CXCR2 is required for neutrophil recruitment to the lung during influenza virus infection, but is not essential for viral clearance. *Viral Immunol.* **2007**, *20*, 369–378.
51. Kugathasan, K.; Roediger, E.; Small, C.; McCormick, S.; Yang, P.; Xing, Z. CD11c+ antigen presenting cells from the alveolar space, lung parenchyma and spleen differ in their phenotype and capabilities to activate naive and antigen-primed T cells. *BMC Immunol.* **2008**, *9*, 1186–1197.
52. Gordon, S.; Read, R. Macrophage defences against respiratory tract infections. *Br. Med. Bull.* **2002**, *61*, 45–61.
53. Gwyer Findlay, E.; Currie, S.; Davidson, D. Cationic host defence peptides: Potential as antiviral therapeutics. *BioDrugs* **2013**, *27*, 479–493.
54. Barlow, P.; Svoboda, P.; Mackellar, A.; Nash, A.; York, I.; Pohl, J.; Davidson, D.; Donis, R. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. *PLoS ONE* **2011**, *6*, e25333.
55. Lai, Y.; Adhikarakunnathu, S.; Bhardwaj, K.; Ranjith-Kumar, C.; Wen, Y.; Jordan, J.; Wu, L.; Dragnea, B.; San Mateo, L.; Kao, C. LL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAs. *PLoS ONE* **2011**, *6*, e26632.
56. Currie, S.; Findlay, E.; McHugh, B.; Mackellar, A.; Man, T.; Macmillan, D.; Wang, H.; Fitch, P.; Schwarze, J.; Davidson, D. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. *PLoS ONE* **2013**, *8*, e73659.
57. Reed, J.; Brewah, Y.; Delaney, T.; Welliver, T.; Burwell, T.; Benjamin, E.; Kuta, E.; Kozhich, A.; McKinney, L.; Suzich, J.; et al. Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. *J. Infect. Dis.* **2008**, *198*, 1783–1793.
58. Schneider, C.; Nobs, S.; Heer, A.; Kurrer, M.; Klinke, G.; van Rooijen, N.; Vogel, J.; Kopf, M. Alveolar macrophages are essential for protection from respiratory failure and associated morbidity following influenza virus infection. *PLoS Pathog.* **2014**, *10*, e1004053.
59. Braciale, T.; Sun, J.; Kim, T. Regulating the adaptive immune response to respiratory virus infection. *Nat. Rev. Immunol.* **2012**, *12*, 295–305.
60. Förster, R.; Davalos-Misslitz, A.; Rot, A. CCR7 and its ligand: Balancing immunity and tolerance. *Nat. Rev. Immunol.* **2008**, *8*, 362–371.
61. Trifilo, M.; Bergmann, C.; Kuziel, W.; Lane, T. CC chemokine ligand 3 (CCL3) regulates CD8(+) T-cells effector function and migration following viral infection. *J. Virol.* **2003**, *77*, 4004–4014.
62. Freeman, C.; Curtis, J.; Chensue, S. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. *Am. J. Pathol.* **2007**, *171*, 767–776.
63. Agostini, C.; Facco, M.; Siviero, M.; Carollo, D.; Galvan, S.; Cattelan, A.; Zambello, R.; Trentin, L.; Semenzato, G. CXC chemokines IP-10 and mig expression and direct migration of pulmonary CD8+/CXCR3+ T cells in the lungs of patients with HIV infection and T-cell alveolitis. *Am. J. Respir. Crit. Care Med.* **2000**, *161* (4 Pt 1), 1466–1473.
64. Bromley, S.; Mempel, T.; Luster, A. Orchestrating the orchestrators: Chemokines in control of T cell traffic. *Nat. Immunol.* **2008**, *9*, 970–980.

65. Gerhard, W. The role of the antibody response in influenza virus infection. *Curr. Top. Microbiol. Immunol.* **2001**, *260*, 171–190.
66. Palladino, G.; Mozdzanowska, K.; Washko, G.; Gerhard, W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. *J Virol.* **1995**, *69*, 2075–2081.
67. Jegaskanda, S.; Weinfurter, J.; Friedrich, T.; Kent, S. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. *J. Virol.* **2013**, *87*, 5512–5522.
68. Stoermer, K.; Morrison, T. Complement and viral pathogenesis. *Virology* **2011**, *411*, 362–373.
69. Zhang, J.; Li, G.; Liu, X.; Wang, Z.; Liu, W.; Ye, X. Influenza A virus M1 blocks the classical complement pathway through interacting with C1qA. *J. Gen. Virol.* **2009**, *90*, 2751–2758.
70. Jones, G. Pharmacokinetics of vitamin D toxicity. *Am. J. Clin. Nutr.* **2008**, *88*, 582–586.
71. Heaney, R. Serum 25-hydroxyvitamin D is a reliable indicator of vitamin D status. *Am. J. Clin. Nutr.* **2011**, *94*, 619–620.
72. Vieth, R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am. J. Clin. Nutr.* **1999**, *69*, 842–856.
73. Norman, A.; Mizwicki, M.; Norman, D. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. *Mat. Rev. Drug Discov.* **2004**, *3*, 27–41.
74. Huhtakangas, J.; Olivera, C.; Bishop, J.; Zanello, L.; Norman, A. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 α -hydroxyvitamin D₃ *in vivo* and *in vitro*. *Mol. Endocrinol.* **2004**, *18*, 2660–2671.
75. Norman, A. Minireview: Vitamin D receptor: New assignments for an already busy receptor. *Endocrinology* **2006**, *147*, 5542–5548.
76. Campbell, F.; Xu, H.; El-Tanani, M.; Crowe, P.; Bingham, V. The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: Operational networks and tissue-specific growth control. *Biochem. Pharmacol.* **2010**, *79*, 1–9.
77. Provvedini, D.; Tsoukas, C.; Deftos, L.; Manolagas, S. 1,25-dihydroxyvitamin D₃ receptors in human leukocytes. *Science* **1983**, *221*, 1181–1183.
78. Baeke, F.; Korf, H.; Overbergh, L.; Etten, E.V.; Verstuyf, A.; Gysemans, C.; Mathieu, C. Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D₃ in the immune system. *J. Steroid Biochem. Mol. Biol.* **2010**, *121*, 221–227.
79. Hewison, M.; Freeman, L.; Hughes, S.; Evans, K.; Bland, R.; Eliopoulos, A.; Kilby, M.; Moss, P.; Chakraverty, R. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. *J. Immunol.* **2003**, *170*, 5382–5390.
80. Chen, S.; Sims, G.; Chen, X.; Gu, Y.; Chen, S.; Lipsky, P. Modulatory effects of 1,25-dihydroxyvitamin D₃ on human B cell differentiation. *J. Immunol.* **2007**, *179*, 1634–1647.
81. Sigmundsdottir, H.; Pan, J.; Debes, G.; Alt, C.; Habtezion, A.; Soler, D.; Butcher, E. DCs metabolize sunlight-induced vitamin D₃ to ‘program’ T cell attraction to the epidermal chemokine CCL27. *Nat. Immunol.* **2007**, *8*, 285–293.
82. Kriegel, M.; Manson, J.; Costenbader, K. Does vitamin D affect risk of developing autoimmune disease?: A systematic review. *Semin. Arthritis Rheum.* **2011**, *40*, 512–531.

83. Krishnan, A.; Trump, D.; Johnson, C.; Feldman, F. The role of vitamin D in cancer prevention and treatment. *Endocrinol. Metab. Clin. North Am.* **2010**, *39*, 401–418.
84. Wang, T.; Pencina, M.; Booth, S.; Jacques, P.; Ingelsson, E.; Lanier, K.; Benjamin, E.; D-Agostino, R.; Wolf, M.; Vasan, R. Vitamin D deficiency and risk of cardiovascular disease. *Circulation* **2008**, *117*, 503–511.
85. Ginde, A.; Mansbach, J.; Camargo, C. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch. Intern. Med.* **2009**, *169*, 384–390.
86. Adams, J.; Ren, S.; Arbelle, J.; Horiuchi, N.; Gray, R.; Clemens, T.; Shany, S. Regulated production and intracrine action of 1,25-dihydroxyvitamin D₃ in the chick myelomonocytic cell line HD-11. *Endocrinology* **1994**, *134*, 2567–2573.
87. Reichel, H.; Koeffler, H.; Barbers, R.; Norman, A. Regulation of 1,25-dihydroxyvitamin D₃ production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. *J. Clin. Endocrinol. Metab.* **1987**, *65*, 1201–1209.
88. Yuan, J.; Freemont, A.; Mawer, E.; Hayes, M. Regulation of 1 alpha, 25-dihydroxyvitamin D₃ synthesis in macrophages from arthritic joints by phorbol ester, dibutyryl-cAMP and calcium ionophore (A23187). *FEBS Lett.* **1992**, *311*, 71–74.
89. Ren, S.; Nguyen, L.; Wu, S.; Encinas, C.; Adams, J.; Hewison, M. Alternative splicing of vitamin D-24-hydroxylase: A novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. *J. Biol. Chem.* **2005**, *280*, 20604–20611.
90. White, J. Vitamin D signaling, infectious diseases, and regulation of innate immunity. *Infect. Immun.* **2008**, *76*, 3837–3843.
91. White, J. Regulation of intracrine production of 1,25-dihydroxyvitamin D and its role in innate immune defense against infection. *Arch. Biochem. Biophys.* **2012**, *523*, 58–63.
92. Campbell, G.; Spector, S. Toll-like receptor 8 ligands activate a vitamin D mediated autophagic response that inhibits human immunodeficiency virus type 1. *PLoS Pathog.* **2012**, *8*, e1003017.
93. Evans, K.; Taylor, H.; Zehnder, D.; Kilby, M.; Bulmer, J.; Shah, F.; Adams, J.; Hewison, M. Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: A novel form of humoral hypercalcemia of malignancy. *Am. J. Pathol.* **2004**, *165*, 807–813.
94. Stoffels, K.; Overbergh, L.; Giulietti, A.; Verlinden, L.; Bouillon, R.; Mathieu, C. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. *J. Bone Miner. Res.* **2006**, *21*, 37–47.
95. Fritzsche, J.; Mondal, K.; Ehrnsperger, A.; Andreesen, R.; Kreutz, M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D₃ by human dendritic cells. *Blood* **2003**, *102*, 3314–3316.
96. Enioutina, E.; Bareyan, D.; Daynes, R. TLR-induced local metabolism of vitamin D₃ plays an important role in the diversification of adaptive immune responses. *J. Immunol.* **2009**, *182*, 4296–4305.
97. Enioutina, E.; Bareyan, D.; Daynes, R. TLR ligands that stimulate the metabolism of vitamin D₃ in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines. *Vaccine* **2008**, *26*, 601–613.

98. Hansdottir, S.; Monick, M.; Hinde, S.; Lovan, N.; Look, D.; Hunninghake, G. Respiratory epithelial cells convert inactive vitamin D to its active form: Potential effects on host defense. *J. Immunol.* **2008**, *181*, 7090–7099.
99. Krutzik, S.; Hewison, M.; Liu, P.; Robles, J.; Stenger, S.; Adams, J.; Modlin, R. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. *J. Immunol.* **2008**, *181*, 7115–7120.
100. Schrumpf, J.; van Sterkenburg, M.; Verhoosel, R.; Zuyderduyn, S.; Hiemstra, P. Interleukin 13 exposure enhances vitamin D-mediated expression of the human cathelicidin antimicrobial peptide 18/LL-37 in bronchial epithelial cells. *Infect. Immun.* **2012**, *80*, 4485–4494.
101. Overbergh, L.; Stoffels, K.; Waer, M.; Verstuyf, A.; Bouillon, R.; Mathieu, C. Immune regulation of 25-hydroxyvitamin D₃ 1 alpha-hydroxylase in human monocytic THP1 cells: Mechanisms of interferon-gamma-mediated induction. *J. Clin. Endocrinol. Metab.* **2006**, *91*, 3566–3574.
102. Edfeldt, K.; Liu, P.; Chun, R.; Fabri, M.; Schenk, M.; Wheelwright, M.; Keegan, C.; Krutzik, S.; Adams, J.; Hewison, M.; et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 22593–22598.
103. Gyetko, M.; Hsu, C.; Wilkinson, C.; Patel, S.; Young, E. Monocyte 1 a lpha-hydroxylase regulation: Induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin. *J. Leukoc. Biol.* **1993**, *54*, 17–22.
104. Slatopolsky, E.; Dusso, A.; Brown, A. New analogs of vitamin D₃. *Kidney Int. Suppl.* **1999**, *73*, S46–S51.
105. Parton, R.; Simons, K. The multiple faces of caveolae. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 185–194.
106. Monkawa, T.; Yoshida, T.; Hayashi, M.; Saruta, T. Identification of 25-hydroxyvitamin D₃ 1alpha-hydroxylase gene expression in macrophages. *Kidney Int.* **2000**, *58*, 559–568.
107. Sørensen, O.; Follin, P.; Johnsen, A.; Calafat, J.; Tjabringa, G.; Hiemstra, P.; VBorregaard, N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. *Blood* **2001**, *97*, 3951–3959.
108. Agerberth, B.; Charo, J.; Werr, J.; Olsson, B.; Idali, F.; Lindblom, L.; Kiessling, R.; Jörnvall, H.; Wigzell, H.; Gudmundsson, G. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. *Blood* **2000**, *96*, 3086–3093.
109. Bals, R.; Wang, X.; Zasloff, M.; Wilson, J. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 9541–9546.
110. Yang, D.; Chen, Q.; Schmidt, A.; Anderson, G.; Wang, J.; Wooters, J.; Oppenheim, J.J.; Chertov, O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPR1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. *J. Exp. Med.* **2000**, *192*, 1069–1074.
111. Tjabringa, G.; Ninaber, D.; Drijfhout, J.; Rabe, K.; Hiemstra, P. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. *Int. Arch. Allergy Immunol.* **2006**, *140*, 103–112.

112. Scott, M.; Davidson, D.; Gold, M.; Bowdish, D.; Hancock, R. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. *J. Immunol.* **2002**, *169*, 3883–3891.
113. Nagaoka, I.; Tamura, H.; Hirata, M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. *J. Immunol.* **2006**, *176*, 3044–3052.
114. Davidson, D.; Currie, A.; Reid, G.; Bowdish, D.; MacDonald, K.; Ma, R.; Hancock, R.; Speert, D. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. *J. Immunol.* **2004**, *172*, 1146–1156.
115. Choi, K.; Chow, L.; Mookherjee, N. Cationic host defence peptides: Multifaceted role in immune modulation and inflammation. *J. Innate Immun.* **2012**, *4*, 361–370.
116. Wang, T.; Nestel, F.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan, J.; Mader, S.; et al. Cutting edge: 1,25-dihydroxyvitamin D₃ is a direct inducer of antimicrobial peptide gene expression. *J. Immunol.* **2004**, *173*, 2909–2912.
117. Gombart, A.; Borregaard, N.; Koeffler, H. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D₃. *FASEB J.* **2005**, *19*, 1067–1077.
118. Yim, S.; Dhawan, P.; Ragunath, C.; Christakos, S.; Diamond, G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). *J. Cyst. Fibros.* **2007**, *6*, 403–410.
119. Weber, G.; Heilborn, J.; Chamorro Jimenez, C.; Hammarsjo, A.; Törmä, H.; Stahle, M. Vitamin D induces the antimicrobial protein hCAP18 in human skin. *J. Investig. Dermatol.* **2005**, *124*, 1080–1082.
120. Ganz, T. Defensins: Antimicrobial peptides of innate immunity. *Nat. Rev. Immunol.* **2003**, *3*, 710–720.
121. Kota, S.; Sabbah, A.; Chang, T.; Harnack, R.; Xiang, Y.; Meng, X.; Bose, S. Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus. *J. Biol. Chem.* **2008**, *283*, 22417–22429.
122. Rigby, W.; Shen, L.; Ball, E.; Guyre, P.; Fanger, M. Differentiation of a human monocytic cell line by 1,25-dihydroxyvitamin D₃ (calcitriol): A morphologic, phenotypic, and functional analysis. *Blood* **1984**, *64*, 1110–1115.
123. Xu, H.; Soruri, A.; Gieseler, R.; Peters, J. 1,25-Dihydroxyvitamin D₃ exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. *Scand. J. Immunol.* **1993**, *38*, 535–540.
124. Wu, S.; Sun, J. Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection. *Discov. Med.* **2011**, *11*, 325–335.
125. Sly, L.; Lopez, M.; Nauseef, W.; Reiner, N. 1alpha,25-Dihydroxyvitamin D₃-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. *J. Biol. Chem.* **2001**, *276*, 35482–35493.
126. Kim, H.; Kim, C.; Ryu, J.; Kim, M.; Park, C.; Lee, J.; Holtzman, M.; Yoon, J. Reactive oxygen species induce antiviral innate immune response through IFN-λ regulation in human nasal epithelial cells. *Am. J. Respir. Cell Mol. Biol.* **2013**, *49*, 855–865.

127. Strengert, M.; Jennings, R.; Davanture, S.; Hayes, P.; Gabriel, G.; Knaus, U. Mucosal reactive oxygen species are required for antiviral response: Role of Duox in influenza A virus infection. *Antioxid. Redox Signal.* **2014**, *20*, 2695–2709.
128. Soucy-Faulkner, A.; Mukawera, E.; Fink, K.; Martel, A.; Jouan, L.; Nzengue, Y.; Lamarre, D.; Vande Velde, C.; Grandvaux, N. Requirement of NOX2 and reactive oxygen species for efficient RIG-I-mediated antiviral response through regulation of MAVS expression. *PLoS Pathog.* **2010**, *6*, e1000930.
129. Liu, G.; Zhai, Q.; Schaffner, D.; Bradburne, C.; Wu, A.; Hayford, A.; Popov, S.; Grene, E.; Bailey, C.; Alibek, K. IL-15 induces IFN-beta and iNOS gene expression, and antiviral activity of murine macrophage RAW 264.7 cells. *Immunol. Lett.* **2004**, *91*, 171–178.
130. Kleinert, H.; Schwarz, P.; Förstermann, U. Regulation of the expression of inducible nitric oxide synthase. *Biol. Chem.* **2003**, *384*, 1343–1364.
131. Lee, Y.; Lai, C.; Hsieh, S.; Shieh, C.; Huang, L.; Wu-Hsieh, B. Influenza A virus induction of oxidative stress and MMP-9 is associated with severe lung pathology in a mouse model. *Virus Res.* **2013**, *178*, 411–422.
132. Ríos-Ibarra, C.; Lozano-Sepulveda, S.; Muñoz-Espinosa, L.; Rincón-Sánchez, A.; Cordova-Fletes, C.; Rivas-Estilla, A. Downregulation of inducible nitric oxide synthase (iNOS) expression is implicated in the antiviral activity of acetylsalicylic acid in HCV-expressing cells. *Arch. Virol.* **2014**, *159*, 3321–3328.
133. Rockett, K.; Brookes, R.; Udalova, I.; Vidal, V.; Hill, A.; Kwiatkowski, D. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. *Infect. Immun.* **1998**, *66*, 5314–5321.
134. Bao, B.; Ting, H.; Hsu, J.; Lee, Y. Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. *Int. J. Cancer* **2008**, *122*, 2699–2706.
135. Chang, J.; Kuo, M.; Kuo, H.; Hwang, S.; Tsai, J.; Chen, H.; Lai, Y. 1-alpha,25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells. *J. Lab. Clin. Med.* **2004**, *143*, 14–22.
136. Gombart, A. *Vitamin D: Oxidative Stress, Immunity, and Aging*; CRC Press: Boca Raton, FL, USA, 2012.
137. Richetta, C.; Faure, M. Autophagy in antiviral innate immunity. *Cell. Microbiol.* **2013**, *15*, 368–376.
138. Yuk, J.; Shin, D.; Lee, H.; Yang, C.; Jin, H.; Kim, K.; Lee, Z.; Lee, S.; Kim, J.; Jo, E. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. *Cell Host Microbe* **2009**, *6*, 231–243.
139. Hoyer-Hansen, M.; Nordbrandt, S.; Jäättelä, M. Autophagy as a basis for the health-promoting effects of vitamin D. *Trends Mol. Med.* **2010**, *16*, 295–302.
140. Sadeghi, K.; Wessner, B.; Laggner, U.; Ploder, M.; Tamandl, D.; Friedl, J.; Zügel, U.; Steinmeyer, A.; Pollak, A.; Roth, E.; et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. *Eur. J. Immunol.* **2006**, *36*, 361–370.

141. Manukyan, M.; Triantafilou, K.; Triantafilou, M.; Mackie, A.; Nilsen, N.; Espevik, T.; Wiesmüller, K.; Ulmer, A.; Heine, H. Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1. *Eur. J. Immunol.* **2005**, *35*, 911–921.
142. Oberg, F.; Botling, J.; Nilsson, K. Functional antagonism between vitamin D₃ and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. *J. Immunol.* **1993**, *150* (8 Pt 1), 3487–3495.
143. Zhang, D.; Hetherington, C.; Gonzalez, D.; Chen, H.; Tenen, D. Regulation of CD14 expression during monocytic differentiation induced with 1 alpha,25-dihydroxyvitamin D₃. *J. Immunol.* **1994**, *153*, 3276–3284.
144. Schauber, J.; Dorschner, R.; Coda, A.; Büchau, A.; Liu, P.; Kiken, D.; Helfrich, Y.; Kang, S.; Elalieh, H.; Steinmeyer, A.; *et al.* Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. *J. Clin. Investig.* **2007**, *117*, 803–811.
145. Wang, T.; Dabbas, B.; Laperriere, D.; Bitton, A.; Soualhine, H.; Tavera-Mendoza, L.; Dionne, S.; Servant, M.; Bitton, A.; Seidman, E.; *et al.* Direct and indirect induction by 1,25-dihydroxyvitamin D₃ of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. *J. Biol. Chem.* **2010**, *285*, 2227–2231.
146. Penna, G.; Adorini, L. 1 A lpha,25-dihydroxyvitamin D₃ inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. *J. Immunol.* **2000**, *164*, 2405–2411.
147. Berer, A.; Stöckl, J.; Majdic, O.; Wagner, T.; Kollars, M.; Lechner, K.; Geissler, K.; Oehler, L. 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation *in vitro*. *Exp. Hematol.* **2000**, *28*, 575–583.
148. Dam, T.; Møller, B.; Hindkjaer, J.; Kragballe, K. The vitamin D₃ analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. *J. Investig. Dermatol. Symp. Proc.* **1996**, *1*, 72–77.
149. Gauzzi, M.; Purificato, C.; Donato, K.; Jin, Y.; Wang, L.; Daniel, K.; Maghazachi, A.; Belardelli, F.; Adorini, L.; Gessani, S. Suppressive effect of 1alpha,25-dihydroxyvitamin D₃ on type I IFN-mediated monocyte differentiation into dendritic cells: Impairment of functional activities and chemotaxis. *J. Immunol.* **2005**, *174*, 270–276.
150. Baeke, F.; Etten, E.; Overbergh, L.; Mathieu, C. Vitamin D₃ and the immune system: Maintaining the balance in health and disease. *Nutr. Res. Rev.* **2007**, *20*, 106–118.
151. D'Ambrosio, D.; Cippitelli, M.; Coccio, M.; Mazzeo, D.; di Lucia, P.; Lang, R.; Sinigaglia, F.; Panina-Bordignon, P. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D₃. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. *J. Clin. Investig.* **1998**, *101*, 252–262.
152. Giovannini, L.; Panichi, V.; Migliori, M.; de Pietro, S.; Bertelli, A.; Fulgenzi, A.; Filippi, C.; Sarnico, I.; Taccola, D.; Palla, R.; *et al.* 1,25-dihydroxyvitamin D(3) dose-dependently inhibits LPS-induced cytokines production in PBMC modulating intracellular calcium. *Transpl. Proc.* **2001**, *33*, 2366–2368.
153. Van Halteren, A.; van Etten, E.; de Jong, E.; Bouillon, R.; Roep, B.; Mathieu, C. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). *Diabetes* **2002**, *71*, 2119–2125.

154. Lemire, J.; Archer, D.; Beck, L.; Spiegelberg, H. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: Preferential inhibition of Th1 functions. *J. Nutr.* **1995**, *125* (Suppl. S6), 1704–1708.
155. Xystrakis, E.; Kusumakar, S.; Boswell, S.; Peek, E.; Urry, Z.; Richards, D.; Adikibi, T.; Pridgeon, C.; Dallman, M.; Loke, T.; *et al.* Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. *J. Clin. Investig.* **2006**, *116*, 146–155.
156. Borish, L.; Aarons, A.; Rumbyrt, J.; Cvietusa, P.; Negri, J.; Wenzel, S. Interleukin-10 regulation in normal subjects and patients with asthma. *J. Allergy Clin. Immunol.* **1996**, *97*, 1288–1296.
157. Tang, J.; Zhou, R.; Luger, D.; Zhu, W.; Silver, P.; Grajewski, R.; Su, S.; Chan, C.; Adorini, L.; Caspi, R. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. *J. Immunol.* **2009**, *182*, 4624–4632.
158. Daniel, C.; Sartory, N.; Zahn, N.; Radeke, H.; Stein, J. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. *J. Pharmacol. Exp. Ther.* **2008**, *324*, 23–33.
159. Miossec, P.; Korn, T.; Kuchroo, V. Interleukin-17 and type 17 helper T cells. *N. Engl. J. Med.* **2009**, *361*, 888–898.
160. Ma, C.; Chew, G.; Simpson, N.; Priyadarshi, A.; Wong, M.; Grimbacher, B.; Fulcher, D.; Tangye, S.; Cook, M. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. *J. Exp. Med.* **2008**, *205*, 1551–1557.
161. Barrat, F.; Cua, D.; Boonstra, A.; Richards, D.; Crain, C.; Savelkoul, H.; de Waal-Malefyt, R.; Coffman, R.; Hawrylowicz, C. *In vitro* generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. *J. Exp. Med.* **2002**, *195*, 603–616.
162. Jeffery, L.; Burke, F.; Mura, M.; Zheng, Y.; Qureshi, O.; Hewison, M.; Walker, L.; Lammas, D.; Raza, K.; Sansom, D. 1,25-dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. *J. Immunol.* **2009**, *183*, 5458–5467.
163. Rigby, W.; Denome, S.; Fanger, M. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. *J. Clin. Investig.* **1987**, *79*, 1659–1664.
164. Cippitelli, M.; Santoni, M. Vitamin D3: A transcriptional modulator of the interferon-gamma gene. *Eur. J. Immunol.* **1998**, *28*, 3017–3030.
165. Boonstra, A.; Barrat, F.; Crain, C.; Heath, V.; Savelkoul, H.; O'Garra, A. 1alpha,25-dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. *J. Immunol.* **2001**, *167*, 4974–4980.
166. Yang, M.; Rui, K.; Wang, S.; Lu, L. Regulatory B cells in autoimmune diseases. *Cell Mol. Immunol.* **2013**, *10*, 122–132.
167. Terrier, B.; Derian, N.; Schindre, Y.; Chaara, W.; Geri, G.; Zahr, N.; Mariampillai, K.; Rosenzwajg, M.; Carpentier, W.; Musset, L.; *et al.* Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. *Arthritis Res. Ther.* **2012**, *14*, R221.

168. Cantorna, M.; Zhao, J.; Yang, L. Vitamin D, invariant natural killer T-cells and experimental autoimmune disease. *Proc. Nutr. Soc.* **2012**, *71*, 62–66.
169. Lysandropoulos, A.; Jaquiéry, E.; Jilek, S.; Pantaleo, G.; Schluep, M.; Du Pasquier, R. Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. *J. Neuroimmunol.* **2011**, *233*, 240–244.
170. Topilski, I.; Flaishon, L.; Naveh, Y.; Harmelin, A.; Levo, Y. and Shachar, I. The anti-inflammatory effects of 1,25-dihydroxyvitamin D₃ on T h2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing. *Eur. J. Immunol.* **2004**, *34*, 1068–1076.
171. Matheu, V.; Back, O.; Mondoc, E.; Issazadeh-Navikas, S. Dual effects of vitamin D-induced alteration of TH1/TH2 cytokine expression: Enhancing IgE production and decreasing airway eosinophilia in murine allergic airway disease. *J. Allergy Clin. Immunol.* **2003**, *112*, 585–592.
172. Staeva-Vieira, T.; Freedman, L. 1,25-dihydroxyvitamin D₃ inhibits IFN-gamma and IL-4 levels in vitro polarization of primary murine CD4+ T cells. *J. Immunol.* **2002**, *168*, 1181–1189.
173. Kreindler, J.; Steele, C.; Nguyen, N.; Chan, Y.; Pilewski, J.; Alcorn, J.; Vyas, Y.; Aujla, S.; Finelli, P.; Blanchard, M.; et al. Vitamin D₃ attenuates Th2 responses to *Aspergillus fumigatus* mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. *J. Clin. Investig.* **2010**, *120*, 3242–3254.
174. Jeffery, L.; Wood, A.; Qureshi, O.; Hou, T.; Gardner, D.; Briggs, Z.; Kaur, S.; Raza, K.; Sansom, D. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. *J. Immunol.* **2012**, *189*, 5155–5164.
175. Arruda, E.; Pitkäranta, A.; Witek, T.; Doyle, C.; Hayden, F. Frequency and natural history of rhinovirus infections in adults during autumn. *J. Clin. Microbiol.* **1997**, *35*, 2864–2868.
176. Kirkpatrick, G. The common cold. *Prim. Care* **1996**, *23*, 657–675.
177. Monto, A. Studies of the community and family: Acute respiratory illness and infection. *Epidemiol. Rev.* **1994**, *16*, 351–373.
178. Brockman-Schneider, R.; Pickles, R.; Gern, J. Effects of vitamin D on airway epithelial cell morphology and rhinovirus replication. *PLoS ONE* **2014**, *9*, e86755.
179. Turner, T.; Kopp, B.; Paul, G.; Landgrave, L.; Hayes, D.; Thompson, R. Respiratory syncytial virus: Current and emerging treatment options. *Clin. Outcomes Res.* **2014**, *25*, 217–225.
180. Borchers, A.; Chang, C.; Gershwin, M.; Gershwin, L. Respiratory syncytial virus—a comprehensive review. *Clin. Rev. Allergy Immunol.* **2013**, *45*, 331–379.
181. Sigurs, N.; Gustafsson, P.; Bjarnason, R.; Lundberg, F.; Schmidt, S.; Sigurbergsson, F.; Kjellman, B. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. *Am. J. Respir. Crit. Care Med.* **2005**, *171*, 137–141.
182. Belderbos, M.; Houben, M.; Wilbrink, B.; Lentjes, E.; Bloemen, E.; Kimpen, J.; Rovers, M.; Bont, L. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. *Pediatrics* **2011**, *127*, e1513–e1520.
183. Drysdale, S.; Prendergast, M.; Alcazar, M.; Wilson, T.; Smith, M.; Zuckerman, M.; Broughton, S.; Rafferty, G.; Johnston, S.; Hodemaekers, H.; et al. Genetic predisposition of RSV infection-related respiratory morbidity in preterm infants. *Eur. J. Pediatr.* **2014**, *173*, 905–912.

184. McNally, J.; Sampson, M.; Matheson, L.; Hutton, B.; Little, J. Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: A systematic review and meta-analysis. *Pediatr. Pulmonol.* **2014**, *49*, 790–799.
185. Kresfelder, T.; Janssen, R.; Bont, L.; Pretorius, M.; Venter, M. Confirmation of an association between single nucleotide polymorphisms in the VDR gene with respiratory syncytial virus related disease in South African children. *J. Med. Virol.* **2011**, *83*, 1834–1840.
186. Randolph, A.; Yip, W.; Falkenstein-Hagander, K.; Weiss, S.; Janssen, R.; Keisling, S.; Bont, L. Vitamin D-binding protein haplotype is associated with hospitalization for RSV bronchiolitis. *Clin. Exp. Allergy* **2014**, *44*, 231–237.
187. Hansdottir, S.; Monick, M.; Lovan, N.; Powers, L.; Gerke, A.; Hunninghake, G. Vitamin D decreases respiratory syncytial virus induction of NF- κ B-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. *J. Immunol.* **2010**, *184*, 965–974.
188. Stoppelenburg, A.; von Hegedus, J.; Huis In't Veld, R.; Bont, L.; Boes, M. Defective control of vitamin D receptor-mediated epithelial STAT1 signaling predisposes to severe respiratory syncytial virus bronchiolitis. *J. Pathol.* **2013**, doi:10.1002/path.4267.
189. Sacco, R.; Nonnecke, B.; Palmer, M.; Waters, W.; Lippolis, J.; Reinhardt, T. Differential expression of cytokines in response to respiratory syncytial virus infection of calves with high or low circulating 25-hydroxyvitamin D3. *PLoS ONE* **2012**, *7*, e33074.
190. McGill, J.; Nonnecke, B.; Lippolis, J.; Reinhardt, T.; Sacco, R. Differential chemokine and cytokine production by neonatal bovine $\gamma\delta$ T-cell subsets in response to viral toll-like receptor agonists and in vivo respiratory syncytial virus infection. *Immunology* **2013**, *139*, 227–244.
191. Khare, D.; Godbole, N.; Pawar, S.; Mohan, V.; Pandey, G.; Gupta, S.; Kiumar, D.; Dhole, T.; Godbole, M. Calcitriol [1, 25(OH)₂ D3] pre- and post-treatment suppresses inflammatory response to influenza A (H1N1) infection in human lung A549 epithelial cells. *Eur. J. Nutr.* **2013**, *52*, 1405–1415.
192. Bermejo-Martin, J.; Ortiz de Lejarazu, R.; Pumarola, T.; Rello, J.; Almansa, R.; Ramirez, P.; Martin-Lloeches, I.; Varillas, D.; Gallegos, M.; Seron, C.; et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. *Crit. Care* **2009**, *13*, R201.
193. Doss, M.; White, M.; Tecle, T.; Gantz, D.; Crouch, E.; Jung, G.; Ruchala, P.; Waring, A.; Lehrer, R.; Hartshorn, K. Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D. *J. Immunol.* **2009**, *182*, 7878–7887.
194. Kriesel, J.; Spruance, J. Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. *Vaccine* **1999**, *17*, 1883–1888.
195. Sundaram, M.; Talbot, H.; Zhu, Y.; Griffin, M.; Spencer, S.; Shay, D.; Coleman, L. Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old. *Vaccine* **2013**, *31*, 2057–2061.
196. Principi, N.; Marchisio, P.; Terranova, L.; Zampiero, A.; Baggi, E.; Daleno, C.; Tirelli, S.; Pelucchi, C.; Esposito, S. Impact of vitamin D administration on immunogenicity of trivalent inactivated influenza vaccine in previously unvaccinated children. *Hum. Vaccin Immunother.* **2013**, *9*, 969–974.

197. Cooper, C.; Thorne, A. Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults. *HIV Clin. Trials* **2011**, *12*, 275–276.
198. Science, M.; Maguire, J.; Russell, M.; Smieja, M.; Walter, S.; Loeb, M. Serum 25-hydroxyvitamin d level and influenza vaccine immunogenicity in children and adolescents. *PLoS ONE* **2014**, *9*, e83553.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).